Overview

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.
Phase:
Phase 3
Details
Lead Sponsor:
Avid Radiopharmaceuticals